Clinically Meaningful Responses to Fremanezumab in Migraine Patients With Medication Overuse and Documented Inadequate Response to 2-4 Migraine Preventive Medications in the Randomized, Placebo-controlled FOCUS Study

Sait Ashina,¹ Verena Ramirez Campos,² Joshua M. Cohen,² Lindsay Janka,² Egilius L.H. Spierings³ ¹Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; ²Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA; ³Boston Headache Institute, Waltham, MA, USA.

Conclusions

Introduction

- Patients who overuse acute medications for migraine generally experience more migraine days, greater migraine severity, and more severe pain intensity¹
- Given the increased disease burden for patients with migraine and acute medication overuse, there is a need for effective preventive medications in this population
- Fremanezumab, a fully humanized monoclonal antibody (IgG2 Δ a) that selectively targets calcitonin gene-related peptide (CGRP),² has proven efficacy for preventive treatment of migraine in adults^{3,4}
- The FOCUS study (ClinicalTrials.gov Identifier: NCT03308968) of fremanezumab was the first and largest study of a migraine preventive treatment in a population of adults with difficult-to-treat migraine and documented inadequate response to 2 to 4 classes of migraine preventive medications⁵

Objective

 To evaluate responder rates (≥50% and ≥75% reductions in the monthly average number of migraine days from baseline) in a subgroup of patients from the FOCUS study with medication overuse (use of any acute medication on ≥15 days/month or triptans/ergots/combination medications on ≥10 days/month) at baseline

ঠ্ৰে Methods


Patients

- This study included adult patients with episodic migraine (EM) or chronic migraine (CM) with documented inadequate response to 2 to 4 classes of prior migraine preventive medications
- This subgroup analysis included patients with medication overuse at baseline (**Box 1**)
- Patients in this subgroup analysis were not detoxified or educated/counseled about the risk of medication overuse

Presented at the PAINWeek Virtual Congress; September 11-13, 2020.

the study, E.L.H. Spierings received research grants from Teva Pharmaceuticals. As an investigator involved in the study, E.L.H. Spierings received research grants from Teva Pharmaceuticals. As an investigator involved in the study, E.L.H. Spierings received research grants from Teva Pharmaceuticals and serves on the speakers bureau for Teva Pharmaceuticals. Is an investigator involved in the study, E.L.H. Spierings received research grants from Teva Pharmaceuticals. As an investigator involved in the study, E.L.H. Spierings received research grants from Teva Pharmaceuticals. As an investigator involved in the study, E.L.H. Spierings received research grants from Teva Pharmaceuticals. As an investigator involved in the study, E.L.H. Spierings received research grants from Teva Pharmaceuticals. As an investigator involved in the study, E.L.H. Spierings received research grants from Teva Pharmaceuticals. As an investigator involved in the study, E.L.H. Spierings received research grants from Teva Pharmaceuticals. As an investigator involved in the study, E.L.H. Spierings received research grants from Teva Pharmaceuticals. As an investigator involved in the study, E.L.H. Spierings received research grants from Teva Pharmaceuticals. As an investigator involved in the study, E.L.H. Spierings received research grants from Teva Pharmaceuticals. As an investigator involved in the study, E.L.H. Spierings received research grants from Teva Pharmaceuticals. As an investigator involved in the study, E.L.H. Spierings received research grants from Teva Pharmaceuticals. As an investigator involved in the study, E.L.H. Spierings received research grants from Teva Pharmaceuticals. As an investigator involved in the study, E.L.H. Spierings received research grants from Teva Pharmaceuticals. As an investigator involved in the study, E.L.H. Spierings received research grants from Teva Pharmaceuticals. As an investigator involved in the study, E.L.H. Spierings received research grants from Teva Pharmaceuticals. As an investigator inv Acknowledgments: This study (ClinicalTrials.gov Identifier: NCT03308968) is funded by Teva Branded Pharmaceutical support were provided by Alyssa Nguyen, PharmD, of MedErgy, and were funded by Teva Pharmaceuticals USA, Inc. References: 1. Schwedt TJ, et al. J Headache Pain. 2018; 319(1): 38. 2. Walter S, Bigal ME. Curr Pain Headache Rep. 2015; 19(3): 6. 3. Dodick DW, et al. JAMA. 2018; 319(19): 1999-2008. 4. Silberstein SD, et al. N Engl J Med. 2017; 377(22): 2113-2122. 5. Ferrari MD, et al. Lancet. 2019; 394(10203): 1030-1040.

• Among patients with medication overuse and documented inadequate response to 2 to 4 classes of migraine preventive medications, significantly higher proportions achieved ≥50% to ≥75% reductions in monthly migraine days after fremanezumab treatment versus placebo • As patients were not counseled about medications in order to be weaned off offending acute medications in order to obtain clinically meaningful responses to fremanezumab



Study Design

Efficacy in Patients With Medication Overuse